Trial
NCT04093648
T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Baylor College of Medicine
Collaborators
The Methodist Hospital Research Institute
Condition
Hepatocellular Carcinoma
Intervention
TEGAR T cells
Why stopped
The key elements of this study were incorporated into another study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-05-20